Patient Preferences and Their Influence on Chronic Hepatitis B-A Review

References

• MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5(5):a021410–a021410. doi:10.1101/cshperspect.a021410
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. The Lancet. 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology. 2017;66(4):1296–1313. doi:10.1002/hep.29323
   PubMed Web of Science ®Google Scholar
• Coffin CS, Zhou K, Terrault NA. New and old biomarkers for diagnosis and management of chronic hepatitis b virus infection. Gastroenterology. 2019;156(2):355–368.e3. doi:10.1053/j.gastro.2018.11.037
   PubMed Web of Science ®Google Scholar
• Kim WR. Emerging therapies toward a functional cure for hepatitis b virus infection. Gastroenterology. 2018;14(7):439–442.
   Google Scholar
• Pham EA, Perumpail RB, Fram BJ, Glenn JS, Ahmed A, Gish RG. Future therapy for hepatitis b virus: role of immunomodulators. Curr Hepatol Rep. 2016;15(4):237–244. doi:10.1007/s11901-016-0315-9
   PubMedGoogle Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Amelung V, Stein V, Suter E, Goodwin N, Nolte E, Balicer R, Handbook Integrated Care. Springer International Publishing; 2021. doi:10.1007/978-3-030-69262-9
   Google Scholar
• Belay YA, Yitayal M, Atnafu A, Taye FA. Patients’ preferences for antiretroviral therapy service provision: a systematic review. Cost Eff Resour Alloc. 2021;19(1):56. doi:10.1186/s12962-021-00310-7
   PubMed Web of Science ®Google Scholar
• Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;38(4):S2–S6. doi:10.1016/j.bone.2006.01.150
   PubMed Web of Science ®Google Scholar
• Allard N, Dev A, Dwyer J, Srivatsa G, Thompson A, Cowie B. Factors associated with poor adherence to antiviral treatment for hepatitis B. J Viral Hepat. 2017;24(1):53–58. doi:10.1111/jvh.12582
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Grossi G, Viganò M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUC s). Liver Int. 2017;37(S1):45–51. doi:10.1111/liv.13291
   PubMedGoogle Scholar
• Wang WX, Jia R, Jin XY, et al. Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients. Front Immunol. 2023;14(1121778). doi:10.3389/fimmu.2023.1121778
   Google Scholar
• Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14(2):434. doi:10.3390/v14020434
   PubMed Web of Science ®Google Scholar
• Krause A, Haberkorn U, Mier W. Strategies for the treatment of HBV/HDV. Eur J Pharmacol. 2018;833:379–391. doi:10.1016/j.ejphar.2018.06.030
   PubMed Web of Science ®Google Scholar
• Lim SG, Aung MO, Chung SW, Soon CS, Mak BH, Lee KH. Patient preferences for hepatitis B therapy. Antivir Ther. 2013;18(5):663–670. doi:10.3851/IMP2482
   PubMed Web of Science ®Google Scholar
• Hardtstock F, Sbarigia U, Kocaata Z, Wilke T, Sylvester SV. Preferences of patients with chronic hepatitis b – A discrete choice experiment on the acceptability of functional cure. Patient Prefer Adherence. 2020;14:613–624. doi:10.2147/PPA.S238833
   PubMed Web of Science ®Google Scholar
• Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis b infection: a review. JAMA. 2018;319(17):1802. doi:10.1001/jama.2018.3795
   PubMed Web of Science ®Google Scholar
• Tan M, Bhadoria AS, Cui F, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(2):106–119. doi:10.1016/S2468-1253(20)30307-1
   PubMed Web of Science ®Google Scholar
• Al Ashgar H, Peedikayil M, Al Quaiz M, et al. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: a randomized controlled study. Saudi J Gastroenterol. 2017;23(3):190. doi:10.4103/sjg.SJG_541_16
   PubMed Web of Science ®Google Scholar
• Huang Y, Qi M, Liao C, et al. Analysis of the efficacy and safety of pegylated interferon-α2b treatment in inactive hepatitis B surface antigen carriers. Infect Dis Ther. 2021;10(4):2323–2331. doi:10.1007/s40121-021-00511-w
   PubMed Web of Science ®Google Scholar
• Tsai TY, Livneh H, Hung TH, Lin IH, Lu MC, Yeh CC. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open. 2017;7(1):e014571. doi:10.1136/bmjopen-2016-014571
   PubMed Web of Science ®Google Scholar
• Tsai TY, Hung TH, Livneh H, Lin IH, Lu MC, Yeh CC. Chinese herbal medicine therapy and the risk of mortality for chronic hepatitis B patients with concurrent liver cirrhosis: a nationwide population-based cohort study. Oncotarget. 2018;9(26):18214–18223. doi:10.18632/oncotarget.24383
   PubMedGoogle Scholar
• Yim HJ, Kim JH, Park JY, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26(4):411–429. doi:10.3350/cmh.2020.0049
   PubMed Web of Science ®Google Scholar
• Wang CS, Lin PJ, Cheng CL, Tai SH, Kao Yang YH, Chiang JH. Detecting potential adverse drug reactions using a deep neural network model. J Med Internet Res. 2019;21(2):e11016. doi:10.2196/11016
   PubMed Web of Science ®Google Scholar
• Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (London, England). 2005;365(9454):123–129. doi:10.1016/S0140-6736(05)17701-0
   PubMed Web of Science ®Google Scholar
• De Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol. 2020;55(5):496–514. doi:10.1007/s00535-020-01680-0
   PubMed Web of Science ®Google Scholar
• Zampino R. Hepatitis B virus burden in developing countries. World J Gastroenterol. 2015;21(42):11941. doi:10.3748/wjg.v21.i42.11941
   PubMed Web of Science ®Google Scholar
• Ginzberg D, Wong RJ, Gish R. Global HBV burden: guesstimates and facts. Hepatol Int. 2018;12(4):315–329. doi:10.1007/s12072-018-9884-8
   PubMed Web of Science ®Google Scholar
• Eliasson L, Clifford S, Mulick A, Jackson C, Vrijens B. How the EMERGE guideline on medication adherence can improve the quality of clinical trials. Br J Clin Pharmacol. 2020;86(4):687–697. doi:10.1111/bcp.14240
   PubMed Web of Science ®Google Scholar
• Chung MK, Kim SS, Cheon YH, et al. Patient perspectives and preferences regarding gout and gout management: impact on adherence. J Korean Med Sci. 2021;36(32):e208. doi:10.3346/jkms.2021.36.e208
   PubMed Web of Science ®Google Scholar
• Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok ASF. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol. 2011;54(1):12–18. doi:10.1016/j.jhep.2010.06.016
   PubMed Web of Science ®Google Scholar
• Lee SB, Jeong J, Park JH, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol. 2020;26(3):364–375. doi:10.3350/cmh.2020.0012
   PubMed Web of Science ®Google Scholar
• Wang L, Chen P, Zheng C. Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B. Infect Drug Resist. 2018;11:2179–2185. doi:10.2147/IDR.S186719
   PubMed Web of Science ®Google Scholar
• Abreu RM, Bassit LC, Tao S, et al. Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic hbv study. Antivir Ther. 2019;24(8):567–579. doi:10.3851/IMP3338
   PubMed Web of Science ®Google Scholar
• Tütüncü EE, Güner R, Gürbüz Y, et al. Adherence to nucleoside/nucleotide analogue treatment in patients with chronic hepatitis B. Balk Med J. 2017;34(6):540–545. doi:10.4274/balkanmedj.2016.1461
   PubMed Web of Science ®Google Scholar
• Kvarnström K, Westerholm A, Airaksinen M, Liira H. Factors contributing to medication adherence in patients with a chronic condition: a scoping review of qualitative research. Pharmaceutics. 2021;13(7):1100. doi:10.3390/pharmaceutics13071100
   PubMed Web of Science ®Google Scholar
• Mühlbacher AC, Bridges JFP, Bethge S, et al. Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment. Eur J Health Econ. 2017;18(2):155–165. doi:10.1007/s10198-016-0763-8
   PubMed Web of Science ®Google Scholar
• Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology. 2005;44(6):762–767. doi:10.1093/rheumatology/keh587
   PubMed Web of Science ®Google Scholar
• Wade R, Paton F, Woolacott N. Systematic review of patient preference and adherence to the correct use of graduated compression stockings to prevent deep vein thrombosis in surgical patients. J Adv Nurs. 2017;73(2):336–348. doi:10.1111/jan.13148
   PubMed Web of Science ®Google Scholar
• Elnaem MH, Rosley NFF, Alhifany AA, Elrggal ME, Cheema E. Impact of pharmacist-led interventions on medication adherence and clinical outcomes in patients with hypertension and hyperlipidemia: a scoping review of published literature. J Multidiscip Healthc. 2020;13:635–645. doi:10.2147/JMDH.S257273
   PubMed Web of Science ®Google Scholar
• Marahrens L, Kern R, Ziemssen T, et al. Patients’ preferences for involvement in the decision-making process for treating diabetic retinopathy. BMC Ophthalmol. 2017;17(1):139. doi:10.1186/s12886-017-0526-z
   PubMed Web of Science ®Google Scholar
• Holmes E, Baker G, Jacoby A, Ring A, Marson A, Hughes D. 1151 Patients’ preferences for anti-epileptic drugs (aeds). J Neurol Neurosurg Psychiatry. 2017;88(Suppl 1):A3.3–A4. doi:10.1136/jnnp-2017-ABN.10
   Google Scholar
• Scheller L, Hilgard G, Anastasiou O, et al. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. Medicine (Baltimore). 2021;100(28):e26571. doi:10.1097/MD.0000000000026571
   PubMed Web of Science ®Google Scholar
• Bartoli A, Gabrielli F, Tassi A, Cursaro C, Pinelli A, Andreone P. Treatments for HBV: a glimpse into the future. Viruses. 2021;13(9):1767. doi:10.3390/v13091767
   PubMed Web of Science ®Google Scholar
• Liu Y, Su M, Lei Y, Tian J, Xue L, Zhang L. Patient preferences for cardiac rehabilitation – a systematic review. Patient Prefer Adherence. 2023;17:75–88. doi:10.2147/PPA.S392417
   PubMed Web of Science ®Google Scholar
• Bhat SA, Ahanger IA, Kazim SN. Forthcoming developments in models to study the hepatitis b virus replication cycle, pathogenesis, and pharmacological advancements. ACS Omega. 2023;8(16):14273–14289. doi:10.1021/acsomega.2c07154
   PubMed Web of Science ®Google Scholar